Pharmacokinetics
Learning Objectives
By the end of this page, you should be able to:
- Trace a drug through the four ADME stages and identify the main factors that alter each stage.
- Explain bioavailability and first-pass metabolism and why they differ across routes of administration.
- Define volume of distribution and explain what a high vs. low Vd tells you about a drug.
- Distinguish Phase I and Phase II metabolism and explain the clinical significance of CYP450 enzymes.
- Explain first-order vs. zero-order kinetics and calculate time to steady state from a half-life.
- Apply pharmacokinetic reasoning to predict how renal or hepatic disease changes dosing.
Quick Answer
Pharmacokinetics (PK) is the study of what the body does to a drug as it moves through four stages, remembered as ADME: Absorption, Distribution, Metabolism, and Excretion. PK determines how much of a dose actually reaches the bloodstream, how it spreads through the body, how it's broken down, and how long it stays before being eliminated. It matters because dosing, dosing frequency, drug interactions, and the need for level monitoring are all pharmacokinetic decisions in disguise — a drug with excellent pharmacodynamics is useless if it never reaches an adequate concentration at its target, or dangerous if it accumulates because the body can't clear it fast enough.
The Four Stages of ADME
Absorption and Bioavailability
Absorption is the movement of a drug from its site of administration into the bloodstream. Oral drugs face the toughest obstacle course: stomach acid, gut wall enzymes, and the first-pass effect — hepatic metabolism of an orally absorbed drug before it ever reaches systemic circulation. This is why oral morphine needs a much higher dose than IV morphine for the same effect, and why drugs like nitroglycerin are given sublingually specifically to bypass the liver on the first pass.
Bioavailability (F) is the fraction of an administered dose that reaches systemic circulation unchanged. IV drugs have F = 100% by definition; oral bioavailability is almost always lower and varies by drug (aspirin ~68%, propranolol ~25% due to heavy first-pass metabolism). Food, gut pH, and drug formulation (immediate vs. extended release) all shift absorption rate and extent.
Distribution and Volume of Distribution
Once absorbed, a drug distributes into tissues. Volume of distribution (Vd) relates the total amount of drug in the body to the plasma concentration: Vd = Dose / Plasma concentration. It is a proportionality constant, not a real anatomical volume.
- A low Vd (close to plasma volume, ~5 L) means the drug stays mostly in the blood (e.g., warfarin, heavily protein-bound).
- A high Vd (much larger than total body water, sometimes hundreds of liters) means the drug has left the blood for tissues like fat or muscle (e.g., digoxin, chloroquine).
Only the unbound (free) fraction of a drug is active and able to cross membranes. Conditions that lower albumin (liver disease, malnutrition) increase the free fraction of highly protein-bound drugs like phenytoin or warfarin, raising toxicity risk even when the "total" drug level looks normal.
Metabolism (Biotransformation)
Metabolism, mostly hepatic, converts drugs into forms that are usually easier to excrete.
- Phase I reactions (oxidation, reduction, hydrolysis) are largely carried out by cytochrome P450 (CYP450) enzymes and often produce an active or even toxic metabolite.
- Phase II reactions (conjugation — glucuronidation, sulfation, acetylation) attach a polar group to make the molecule water-soluble for excretion. Acetaminophen undergoes both: Phase I oxidation produces the toxic metabolite NAPQI, which Phase II glutathione conjugation normally detoxifies — until glutathione stores are exhausted in overdose.
CYP450 enzymes explain most clinically important drug-drug interactions: inducers (rifampin, carbamazepine, phenytoin) speed up metabolism of co-administered drugs, lowering their effect; inhibitors (ketoconazole, ritonavir, grapefruit juice via CYP3A4) slow metabolism, raising drug levels and toxicity risk.
Excretion, Clearance, and Half-Life
Excretion — mainly renal, with lesser roles for bile, lungs, and sweat — removes the drug or its metabolites. Clearance (CL) is the volume of plasma completely cleared of drug per unit time. Most drugs follow first-order kinetics: a constant fraction is eliminated per unit time, giving an exponential decay curve.
Half-life (t½) is the time for plasma concentration to fall by 50%, and it predicts two clinically vital numbers:
- Time to reach steady state with repeated dosing: ~4-5 half-lives, regardless of dose or frequency.
- Time to eliminate a drug after stopping: also ~4-5 half-lives to reach a clinically negligible level.
A small number of drugs (ethanol at higher doses, phenytoin, aspirin in overdose) follow zero-order kinetics, where a constant amount is eliminated per unit time because the metabolizing enzyme is saturated — dangerous because small dose increases can cause disproportionately large increases in plasma level.
Worked Examples
Aspirin: well absorbed orally (bioavailability ~68%), metabolized hepatically; at toxic doses, metabolism saturates and shifts from first-order to zero-order kinetics, which is why aspirin overdose is unpredictable and dangerous.
Warfarin: highly protein-bound (~99%) and has a low Vd, staying mostly in the bloodstream; a drop in albumin or displacement by another highly protein-bound drug increases the free (active) fraction and bleeding risk even though the total measured level may look unchanged.
Digoxin: has a very high Vd (accumulates in muscle and other tissue), which is clinically important because a patient in digoxin toxicity cannot be effectively treated by hemodialysis — the drug isn't in the blood to be filtered out.
Key Terms
| Term | Definition |
|---|---|
| Absorption | Movement of a drug from its site of administration into the bloodstream |
| Bioavailability (F) | Fraction of an administered dose reaching systemic circulation unchanged |
| First-pass effect | Hepatic metabolism of an orally absorbed drug before it reaches systemic circulation |
| Volume of distribution (Vd) | Theoretical volume relating total drug in the body to plasma concentration |
| Clearance (CL) | Volume of plasma cleared of drug per unit time |
| Half-life (t½) | Time for plasma drug concentration to fall by 50% |
| First-order kinetics | Constant fraction of drug eliminated per unit time (most drugs) |
| Zero-order kinetics | Constant amount of drug eliminated per unit time (enzyme saturation) |
| CYP450 enzymes | Liver enzyme family responsible for most Phase I drug metabolism |
| Steady state | The point where drug administration rate equals elimination rate |
Common Mistakes
Misconception 1: "Half-life tells you how long a drug's clinical effect lasts." Why it's wrong: half-life describes plasma concentration decay, not duration of clinical effect, which also depends on receptor binding kinetics, active metabolites, and the therapeutic window. Correct: use half-life to predict time to steady state and time to elimination (~4-5 half-lives each); judge clinical duration of action from the drug's actual pharmacodynamic profile — aspirin's antiplatelet effect outlasts its short plasma half-life because it irreversibly inhibits COX in platelets for their entire lifespan.
Misconception 2: "Doubling the maintenance dose gets you to steady state twice as fast." Why it's wrong: doubling the maintenance dose does double the steady-state concentration, but time to steady state depends only on half-life, not dose or dosing interval. Correct: to reach a therapeutic level faster, give a loading dose (calculated from Vd), not a larger maintenance dose.
Misconception 3: "A drug's total plasma level always tells you how much active drug is present." Why it's wrong: for highly protein-bound drugs, only the unbound (free) fraction is pharmacologically active; total level can look normal while the free, active fraction rises due to low albumin or displacement interactions. Correct: for narrow therapeutic index, highly protein-bound drugs (phenytoin, warfarin), consider free levels or clinical signs, not total drug level alone, especially in liver disease or hypoalbuminemia.
Comparison and Connections
| Concept A | Concept B | Key Difference |
|---|---|---|
| Absorption | Distribution | Absorption = drug entering the bloodstream; distribution = drug leaving the bloodstream for tissues |
| First-order kinetics | Zero-order kinetics | First-order = constant fraction eliminated; zero-order = constant amount eliminated (enzyme saturation) |
| Bioavailability | Clearance | Bioavailability = how much drug gets in; clearance = how fast the body removes it |
| Phase I metabolism | Phase II metabolism | Phase I modifies the molecule (oxidation/reduction, may create active/toxic metabolites); Phase II conjugates it for excretion |
| Loading dose | Maintenance dose | Loading dose (based on Vd) rapidly achieves target concentration; maintenance dose (based on clearance) sustains it |
Practice Questions
Recall
- What are the four processes of pharmacokinetics, in order? Answer guidance: Absorption → Distribution → Metabolism → Excretion (ADME).
- Define bioavailability and state its value for an IV drug. Answer guidance: bioavailability is the fraction of an administered dose reaching systemic circulation unchanged; for IV drugs, F = 100%.
Understanding
- Explain why it takes roughly 4-5 half-lives to reach steady state regardless of the dose given. Answer guidance: steady state occurs when drug administration rate equals elimination rate; because elimination is a fixed fraction per half-life (first-order kinetics), time to reach this equilibrium depends only on the elimination rate constant (half-life), not dose size.
- Why does a high volume of distribution make a drug harder to remove by dialysis in an overdose? Answer guidance: a high Vd means most of the drug has left the bloodstream and is sequestered in tissues (fat, muscle), so dialysis — which only filters blood — cannot access or remove the majority of the drug.
Application
- A drug has a half-life of 8 hours. Approximately how long will it take to reach steady-state plasma concentration on a fixed dosing schedule? Answer guidance: ~32-40 hours (4-5 half-lives x 8 hours).
- A patient with liver cirrhosis and low albumin is started on phenytoin. What pharmacokinetic change should you anticipate, and why does it matter clinically? Answer guidance: low albumin increases the free (unbound, active) fraction of phenytoin even though the total measured level may look normal, raising toxicity risk — clinicians should monitor free levels or clinical signs rather than total level alone.
Analysis
- Compare how a loading dose and a maintenance dose each achieve their pharmacokinetic goal, and explain why giving only a larger maintenance dose is not an adequate substitute for a loading dose in an urgent situation. Answer guidance: a loading dose is calculated from Vd to rapidly fill the distribution volume and reach a target concentration immediately; a maintenance dose is calculated from clearance to sustain that concentration at steady state, but increasing it alone does not shorten the ~4-5 half-life time needed to reach steady state through ongoing dosing.
- Explain the mechanism by which aspirin overdose shifts from first-order to zero-order kinetics, and why this makes toxicity management harder. Answer guidance: at toxic doses, the hepatic enzymes metabolizing salicylate become saturated, so only a fixed amount (not fraction) is cleared per unit time; plasma levels can then rise disproportionately with small additional exposure, and clearance no longer scales predictably, making it difficult to anticipate how long toxic levels will persist.
FAQ
Q1: Why do oral drugs often need a higher dose than IV drugs for the same effect? Because oral drugs undergo first-pass hepatic metabolism before reaching systemic circulation, reducing their bioavailability; IV drugs enter the bloodstream directly with F = 100%.
Q2: Does a higher volume of distribution mean a drug is more dangerous? Not directly — it tells you the drug has left the bloodstream for tissues, which matters for dosing (loading dose calculations) and for why hemodialysis often fails to remove high-Vd drugs in overdose.
Q3: Why does grapefruit juice interact with so many medications? Grapefruit juice inhibits intestinal CYP3A4, reducing first-pass metabolism of many oral drugs (certain statins, calcium channel blockers) and raising their blood levels, sometimes into the toxic range.
Q4: How is clearance different from half-life? Clearance is the volume of plasma cleared of drug per unit time (a rate); half-life is the time for concentration to fall by half (derived from clearance and volume of distribution together) — two drugs can share a half-life but have very different clearance and Vd values.
Q5: Why do drug doses need adjusting in kidney or liver disease? Because the kidney and liver are the primary organs for excretion and metabolism respectively — impaired function slows drug elimination, raising plasma levels and toxicity risk unless the dose or interval is adjusted.
Quick Revision
- ADME order: Absorption → Distribution → Metabolism → Excretion.
- Oral drugs undergo first-pass hepatic metabolism before reaching systemic circulation; IV bypasses this entirely (F = 100%).
- Bioavailability (F) = fraction of dose reaching systemic circulation unchanged.
- Volume of distribution (Vd) = Dose / Plasma concentration; high Vd = tissue accumulation, low Vd = stays in blood.
- Only the free (unbound) drug fraction is pharmacologically active; low albumin raises free fraction of highly protein-bound drugs.
- Phase I metabolism (CYP450-mediated oxidation/reduction) may create active or toxic metabolites; Phase II conjugation makes drugs water-soluble for excretion.
- CYP450 inducers (rifampin, carbamazepine) lower co-administered drug levels; inhibitors (ketoconazole, grapefruit juice) raise them.
- Most drugs follow first-order kinetics (constant fraction eliminated); some (ethanol, phenytoin, aspirin in overdose) follow zero-order kinetics once enzymes saturate.
- Time to steady state and time to elimination both ≈ 4-5 half-lives, independent of dose.
- A loading dose (based on Vd) reaches target concentration quickly; a maintenance dose (based on clearance) sustains it.
- Renal and hepatic impairment slow excretion and metabolism respectively, often requiring dose or interval adjustment.
Related Topics
Prerequisites
Related Topics
Next Topics